ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH

INNOVARE ACADEMIC SCIENCES
Knowledge to Innovation

Vol 18, Issue 5, 2025

Online - 2455-3891
Print - 0974-2441

Review Article

REGULATORY CONSIDERATIONS ON ADDITIONAL RISK MINIMIZATION MEASURES IN EUROPE

JOHN GIRIDHARAN IVR[1]*, SRINIVASAN R[2]

[1]Department of Drug Regulatory Affairs, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India. [2]Departmental Pharmaceutical Chemistry and Analysis, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.

***Corresponding author: John Giridharan IVR; Email: giridharanjohn1@gmail.com; girirayar@yahoo.com**

Received: 2 March 2025, Revised and Accepted: 19 April 2025

ABSTRACT

Additional risk minimization measures (aRMMs) are crucial in the European regulatory framework to enhance pharmaceutical safety when routine risk management strategies are inadequate. These measures are implemented when a medicinal product poses risks such as severe adverse reactions, misuse, or teratogenicity, which cannot be adequately controlled through standard pharmacovigilance processes. In Europe, the European Medicines Agency (EMA) plays a central role in overseeing the development, implementation, and monitoring of aRMMs, ensuring that these strategies are both effective and compliant with European Union (EU) pharmacovigilance legislation. While prior reviews have examined pharmacovigilance strategies, gaps remain in assessing the real-world implementation challenges of aRMMs, their regulatory effectiveness, and their impact on healthcare systems and patient access. Current regulatory reviews have not comprehensively addressed the evolving complexities of compliance with EU pharmacovigilance legislation, particularly in balancing stringent safety requirements with practical drug accessibility. This review bridges these gaps by analyzing the regulatory framework governing aRMMs, including legal mandates for risk management plans, post-marketing surveillance strategies, and ongoing safety monitoring through registries and studies. By offering a novel perspective on optimizing aRMM implementation and identifying areas for regulatory enhancement, this review contributes to a more comprehensive understanding of risk minimization strategies. It stresses the necessity for continuous evaluation and adaptation to ensure that pharmaceutical benefits outweigh risks while maintaining accessibility.

Keywords: Additional risk minimization measures, Risk management plan, Risk minimization strategy, Monitoring and reporting.

 DOI: http://dx.doi.org/10.22159/ajpcr.2025v18i5.54374. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr

INTRODUCTION

In Europe, the safeguarding of pharmaceutical products remains a paramount concern for regulatory bodies such as the European Medicines Agency (EMA) and national competent authorities (NCAs). While routine pharmacovigilance activities, including the monitoring of adverse drug reactions and post-market surveillance, are fundamental to ensuring drug safety, there are instances where supplementary risk minimization strategies are deemed necessary to mitigate residual risks associated with certain medicinal products. These additional measures are typically mandated by the EMA or relevant national regulatory agencies, and their implementation is contingent on the specific risks identified during clinical trials or the post-marketing phase of a product's lifecycle [1].

Pharmaceutical risk minimization measures (RMMs) encompass a range of strategies and actions employed by regulatory authorities and pharmaceutical companies to mitigate the potential risks associated with the utilization of a medicinal product [2]. These measures form an integral component of the broader pharmacovigilance framework and are designed to ensure that the therapeutic benefits of a drug remain outweighed by its risks once it is introduced to the market and administered to the general populace. The primary aim of risk minimization is to guarantee the safe and effective use of pharmaceutical agents by identifying and addressing risks that may not have been fully recognized during clinical trials or that arise subsequently on the drug's use in a more expansive and heterogeneous population. Such risks may include adverse drug reactions (ADRs), drug-drug interactions, misuse, abuse, and specific safety concerns pertinent to vulnerable patient groups [3].

This review aims to provide a comprehensive analysis of additional risk minimization measures (aRMMs) within the European regulatory framework, evaluating their implementation challenges, regulatory effectiveness, and impact on healthcare systems and patient access [4]. It examines various risk minimization strategies, including routine and additional measures, while exploring the EMA's role in overseeing their regulation and monitoring. The review investigates legal mandates for risk management plans (RMPs), post-marketing surveillance strategies, and real-world challenges such as compliance complexities and healthcare system integration. It contrasts European Union (EU) risk management strategies with those in the United States, assesses existing tools for risk evaluation, and discusses optimization strategies to enhance patient safety. Finally, it proposes recommendations to improve aRMM implementation, ensuring a balance between stringent safety requirements and practical drug accessibility [5].

METHODS

A systematic approach was employed to gather relevant literature and regulatory information through various online platforms and databases. Several search engines and academic resources, such as Science Direct, Google Scholar, and others, were utilized to obtain peer-reviewed articles, research studies, and academic papers pertinent to the topic. In addition to scholarly articles, online books and e-books served as valuable sources of supplementary information, offering in-depth perspectives on pharmaceutical safety, regulatory frameworks, and risk management strategies. Furthermore, authoritative regulatory websites were thoroughly examined to ensure the inclusion of current and comprehensive guidelines. Notably, the EMA website was a central repository for official documents, offering direct access to crucial resources regarding pharmaceutical regulation and RMMs. Specific regulatory documents accessed from these websites included:

EMA official website

Access to the latest updates on regulatory practices, guidelines, and pharmacovigilance activities related to medicinal products was obtained from the EMA's official portal (https://www.ema.europa.eu/en). This website provides a wealth of information on drug safety, approval processes, and post-market surveillance initiatives within the EU.

EMA risk management guidelines

Detailed review of the EMA's pharmacovigilance guidelines, such as Directive 2010/84/EU and Regulation (EC) No 1235/2010, which provide the legal framework for risk minimization strategies for medicinal products in Europe. These documents offer critical insights into the legal requirements and regulatory obligations surrounding risk management, detailing the necessary steps for the development and implementation of RMPs, post-marketing surveillance, and aRMMs.

By consulting these resources, a comprehensive understanding of the regulatory environment and best practices for risk management in the pharmaceutical industry was achieved, facilitating an informed and well-rounded analysis of the subject matter.

COMPREHENSIVE RISK MANAGEMENT IN PHARMACEUTICAL SAFETY

Risk assessment in pharmaceuticals is an essential process aimed at identifying, evaluating, and managing the potential risks associated with a drug throughout its lifecycle. The process begins with risk identification, which entails recognizing possible hazards such as adverse drug reactions, drug interactions, misuse, or long-term effects. Risk characterization follows, focusing on the nature, severity, and frequency of these risks, particularly in relation to specific patient populations or conditions. This is followed by risk evaluation, where the identified risks are weighed against the therapeutic benefits of the drug to determine whether the benefits justify the potential harms. If risks are deemed significant in aRMMs, aRMMs, such as labeling modifications, restricted distribution, or enhanced clinical monitoring, may be instituted [6,7]. Risk monitoring continues post-market, leveraging surveillance systems to detect emerging adverse events that were not observed during clinical trials [8]. The overarching goal of risk assessment is to safeguard patient safety by balancing therapeutic efficacy with potential harm, ensuring ongoing risk mitigation as new data becomes available. Risk communication, a pivotal element of pharmacovigilance, refers to the process of disseminating information about the risks associated with a drug to healthcare professionals (HCPs), patients, and the public, emphasizing the importance of understanding the risks, their likelihood, and the necessary actions to mitigate them [9]. This can take various forms, including product labeling, patient information leaflets (PILs), HCP training, and safety alerts. The effectiveness of risk communication lies in its ability to provide clear, transparent, and timely information, enabling informed decisions by healthcare providers and ensuring that patients are equipped to use the medication safely. Risk minimization strategies are actions taken when routine risk management measures are insufficient, particularly for drugs with serious identified risks. These strategies may involve restricting distribution to specific settings or prescribers, requiring specialized healthcare provider training, or implementing mandatory monitoring programs for patients. For drugs with teratogenic risks, such as isotretinoin, pregnancy prevention programs (PPPs) may be enforced, including mandatory pregnancy testing and contraception use [10]. Other strategies include establishing patient registries to monitor long-term safety, limiting drug use to particular populations, and ensuring clear communication regarding safe medication usage. Tailored to the specific risk profiles of individual drugs, these strategies are designed to ensure that the benefits of the medication outweigh the risks when appropriately managed.

RMMs CAN BE CATEGORIZED INTO TWO BROAD CATEGORIES

RMMs: Routine and additional approaches in pharmaceutical safety

Routine RMMs

Routine RMMs represent standardized and widely adopted strategies designed to mitigate the risk of adverse events across the majority of pharmaceutical products [11]. These measures are embedded in regulatory frameworks and serve as essential tools in ensuring patient safety throughout a drug's lifecycle.

Labeling/package insert

The labeling and package insert serve as primary communication tools, providing critical information about the drug's potential risks, contraindications, and instructions for safe use [12]. These documents are required by regulatory authorities and are essential for both healthcare providers and patients to understand the therapeutic profile and potential dangers associated with a medication. Labeling also includes specific warnings and precautions to minimize misuse and adverse effects.

PILs

These leaflets offer detailed instructions and safety information tailored to the patient's understanding, ensuring they are well-informed about proper medication usage, potential side effects, and what to do in case of adverse reactions. By providing clear, comprehensible instructions, PILs serve as a vital tool for enhancing patient safety, promoting adherence to prescribed regimens, and preventing harm caused by improper use [13].

HCP communication

This category includes structured communications such as safety alerts, clinical guidelines, and prescriber recommendations that are disseminated to HCPs [14]. These communications are crucial in guiding practitioners on how to safely prescribe and monitor the use of a drug, ensuring that they are well-equipped to manage any potential risks associated with its use. Regular updates, advisories, and best practice recommendations help to maintain safety standards in clinical settings and foster informed decision-making.

aRMMS

aRMMs are implemented when routine risk management strategies are insufficient to address specific risks associated with a particular drug. These measures are generally more tailored and proactive, designed to mitigate severe or unique risks that routine risk minimization cannot effectively control. The implementation of aRMMs is often triggered when there is evidence suggesting that a drug presents significant hazards, such as severe adverse reactions, teratogenicity, misuse, or other risks that may not be fully mitigated through standard pharmacovigilance measures [15]. These targeted interventions may include the restriction of drug distribution to specific healthcare settings or prescribers, thereby ensuring that only qualified professionals are responsible for its prescription. In some cases, specialized training programs for healthcare providers are mandated to ensure that they are fully equipped to recognize, monitor, and manage the risks associated with the drug. aRMMs may include the establishment of patient registries, which are used to monitor long-term safety data and provide additional insights into adverse events that may not have been identified during clinical trials [16]. In some cases, mandatory monitoring programs may be introduced to track patient health outcomes and detect any emerging side effects. Ultimately, aRMMs are designed to bridge the gap between routine risk management and more complex, drug-specific risks, ensuring that patient safety is upheld through enhanced regulatory oversight and tailored intervention strategies.

aRMMS IN EUROPE

In the EU, the imposition of aRMMs is mandated when a medicinal product is deemed to present an elevated level of risk to patient safety. These measures are an integral component of the RMP, a comprehensive document that must be submitted by the marketing authorization holder (MAH) to the EMA or the relevant competent authority, depending on the specific regulatory procedures under which the product is approved [17]. The RMP serves as a framework for the systematic assessment, identification, and mitigation of potential risks associated with medicinal products throughout their

lifecycle. The principal objective of aRMMs is to mitigate serious and identified risks that cannot be sufficiently controlled through routine pharmacovigilance practices alone. These routine practices typically include monitoring ADRs, conducting post-market surveillance, and employing risk communication strategies. However, certain products, particularly those with complex safety profiles or novel therapeutic mechanisms, may necessitate more stringent and tailored interventions to ensure that the benefit-risk balance remains favorable for patients. aRMMs may encompass a range of strategies, including but not limited to restricted distribution systems, risk communication plans (RCPs), additional labeling requirements, or mandatory patient monitoring programs [18]. The specific nature and scope of these measures are determined based on a thorough risk assessment conducted during the clinical development phase and continuously updated throughout the post-marketing period. As part of the regulatory oversight process, the EMA or the competent national authorities evaluate the effectiveness of these aRMMs, ensuring that they are appropriately designed and implemented to mitigate risks while facilitating patient access to essential therapies. Thus, aRMMs represent a critical tool in the broader pharmacovigilance and risk management framework, designed to safeguard public health and maintain therapeutic efficacy [19].

TYPES OF ARMMS IN THE EU

The specific aRMMs may vary depending on the nature of the risk, but they generally involve one or more of the following:

RCPs

In the EU, RCPs represent a critical component of a medicinal product's broader RMP, particularly for pharmaceuticals associated with significant safety concerns. These plans are meticulously developed to ensure that HCPs, patients, and other relevant stakeholders are adequately apprised of the inherent risks associated with a given medicinal product, as well as the corresponding strategies necessary to mitigate such risks. Typically, these plans encompass a diverse array of communication strategies, including the updating of product labeling, the distribution of comprehensive PILs, and direct correspondence with healthcare providers, such as safety alerts and risk communication letters [20]. A well-constructed RCP incorporates several pivotal elements, including the identification of the target audience, the customization of messaging to address the specific risk profile of the product, the selection of appropriate communication channels, and the assurance of the timely and effective distribution of safety-related information. Moreover, the evaluation of the efficacy of these communication efforts is essential to confirm that the intended audience not only receives but also comprehends the risk-related information. Regulatory oversight by the EMA and national regulatory authorities plays an indispensable role in ensuring that risk communications are disseminated to the appropriate recipients and are conveyed in a manner that promotes the safe and informed use of the medicinal product [21].

Restricted distribution systems

These systems are designed to circumscribe the availability or accessibility of a pharmaceutical agent to select healthcare environments, prescribing professionals, or specific patient populations, thereby ensuring its prudent and controlled utilization. For instance, a drug with significant risks, such as teratogenicity or the potential for severe adverse effects, may be dispensed exclusively through specialized hospitals, pharmacies, or clinicians who have undergone rigorous training to ensure the drug's safe administration [22]. In some instances, patients may be required to participate in a specific enrollment program or fulfill predefined criteria before being granted access to the medication. Restricted distribution systems serve as a critical safeguard, minimizing the exposure of high-risk groups, facilitating the implementation of rigorous monitoring protocols, and preventing the potential for misuse or inappropriate overuse [23]. These systems are meticulously outlined in the RMP submitted by the MAH and necessitate approval from regulatory bodies such as the EMA or other competent authorities. The primary objective of these systems is to ensure that the therapeutic benefits of the drug outweigh its associated risks, even when prescribed and utilized under highly controlled conditions. Examples of such systems include Risk Evaluation and Mitigation Strategies in the United States and restricted access programs implemented across Europe [24].

Patient and HCP education

Specialized training programs for healthcare providers are essential to ensure the safe prescribing and monitoring of pharmaceutical products, particularly those associated with significant risks. These programs are designed to impart in-depth knowledge regarding the pharmacological characteristics of the drug, its potential adverse effects, and the requisite monitoring protocols to identify and manage any complications that may arise during treatment. Such training is crucial for equipping HCPs with the necessary skills to make informed decisions, recognize early signs of adverse reactions, and implement appropriate interventions when required. In tandem with healthcare provider education, patient education initiatives play a pivotal role in safeguarding therapeutic outcomes, particularly in cases where medications demand meticulous monitoring or self-administration [25]. These educational programs are structured to inform patients about the inherent risks of the drug, appropriate usage instructions, and essential precautions to mitigate potential harm [26]. Information is typically disseminated through a variety of channels, including PILs, risk communication letters, and dedicated counseling sessions. These resources provide patients with comprehensive guidance on the drug's administration, warning signs of adverse effects, and the necessary steps to take in the event of an emergency. Such educational efforts not only enhance patient adherence to prescribed regimens but also foster a collaborative approach to healthcare where both patients and providers are vigilant and informed. Regulatory authorities, including the EMA and national bodies, often mandate these educational initiatives as a requisite component of the RMP for certain medications, particularly those with complex or high-risk safety profiles, ensuring that both healthcare providers and patients are adequately prepared to manage the drug's risks effectively [27].

PPPs

Certain pharmaceuticals associated with teratogenic risks – those capable of inducing congenital malformations if administered during pregnancy – necessitate the implementation of specialized risk management programs [28]. These programs are particularly pivotal for medications indicated for severe or life-threatening conditions, where the therapeutic benefit for the pregnant patient is outweighed by the potential harm to fetal development. Drugs such as isotretinoin, thalidomide, and select oncological therapies are subject to stringent regulatory oversight, as mandated by the EMA. For these substances, the EMA enforces rigorous controls that include requirements for women of childbearing potential to undergo pregnancy testing both before initiation and periodically throughout the course of treatment [29]. Furthermore, patients are obligated to employ dual forms of contraception during the treatment period and for a designated duration following its cessation. Healthcare providers are additionally responsible for ensuring comprehensive patient education regarding the associated risks, facilitating informed consent, and enrolling patients in a formal risk management program. These measures are meticulously designed to mitigate the risk of unintended pregnancies and safeguard against the deleterious effects of drug-induced teratogenicity, thereby ensuring the safe prescription and administration of these high-risk medications.

Registry and follow-up studies

Patient registries and follow-up studies serve as critical instruments in the mitigation of risks associated with pharmaceuticals, particularly for medications that pose significant or long-term safety concerns. Such studies are frequently mandated for drugs that may induce rare or delayed adverse effects, which may not be adequately identified during the controlled environment of clinical trials. These studies are

particularly vital for medications used in specific, often vulnerable, patient populations that necessitate continuous monitoring throughout their usage [30]. Typically, a patient registry is established to systematically track the health outcomes of individuals using the medication, thereby facilitating the collection of data on adverse events, therapeutic effectiveness, and long-term safety profiles. Follow-up studies, which may involve regular clinical evaluations or longitudinal data collection, are designed to identify potential risks or emerging issues that may only manifest after prolonged drug exposure or within a more diverse patient cohort. These registries and studies are integral components of a drug's comprehensive RMP, ensuring their alignment with regulatory requirements [31]. They are overseen by the EMA and national regulatory bodies, which utilize the amassed real-world data to ensure sustained drug safety. Furthermore, these data inform ongoing regulatory decisions related to risk minimization strategies or potential modifications to drug labeling, ensuring that patient safety remains paramount throughout the drug's lifecycle.

Prescription control

Certain high-risk pharmaceutical agents may be accessible exclusively through designated distribution channels, such as specialized pharmacies or on issuance of a written prescription from a qualified specialist. Prescription control mechanisms often involve the limitation of a drug's availability to specific healthcare environments, such as hospitals or specialized clinics, and the restriction of its prescription to highly trained specialists, such as oncologists or cardiologists, depending on the pharmacological risk profile of the medication. A prime example of such regulation can be observed in drugs with severe adverse risk potential, such as thalidomide or certain opioids, which necessitate that prescribers undergo certification or participate in restricted prescribing programs [32]. The underlying objective of these prescription control strategies is to protect patients by ensuring that these potent medications are administered solely when clinically indicated and under the most stringent safety protocols, accompanied by rigorous monitoring to identify and mitigate any emergent adverse effects.

Patient monitoring

For pharmaceutical agents associated with significant risks, such as organ toxicity, cardiovascular complications, or severe immunosuppression, patients are often required to undergo routine and comprehensive monitoring procedures throughout the course of treatment. These monitoring protocols are meticulously delineated within the drug's RMP and typically encompass a range of diagnostic assessments, including blood tests, imaging studies, and other pertinent screenings designed to detect early manifestations of adverse reactions [18]. For instance, individuals prescribed immunosuppressive medications may necessitate frequent blood examinations to assess for indicators of infection or organ impairment. The responsibility for ensuring patient compliance with these monitoring requirements lies with healthcare providers, who must vigilantly oversee the adherence to scheduled assessments. Furthermore, the EMA and national regulatory bodies play a pivotal role in regulating and supervising the implementation of these monitoring strategies to safeguard patient well-being. Early detection through rigorous patient monitoring facilitates the timely identification of emerging risks, thereby enabling prompt medical intervention and ensuring that the therapeutic benefits of the drug consistently outweigh the associated risks [33].

Risk minimization programs for specific populations

These programs are customarily instituted for pharmaceuticals associated with well-documented risks that disproportionately impact vulnerable populations, such as pediatric patients, the elderly, pregnant women, or individuals with pre-existing comorbidities. For instance, a drug contraindicated during pregnancy may necessitate stringent precautionary measures, including mandatory pregnancy testing or the use of contraception for women of childbearing potential, as exemplified by medications like isotretinoin [34]. Likewise, drugs known to pose increased risks for the elderly, such as those inducing sedation or increasing the likelihood of falls, may require adjustments to dosage regimens or more intensive monitoring protocols. These measures are integral components of a drug's RMP, structured to ensure that the therapeutic benefits of the medication consistently outweigh the associated risks when administered to these particularly susceptible cohorts. Oversight of the effectiveness of such programs is rigorously conducted by the EMA and pertinent national authorities, ensuring that all special requirements tailored to these populations are meticulously enforced, thereby minimizing potential harm and safeguarding public health.

FEW EXAMPLES OF aRMMS IN EUROPE

Isotretinoin: A pharmaceutical agent primarily indicated for the management of severe, recalcitrant acne, is associated with a significantly elevated risk of teratogenicity. Due to its potential to induce severe congenital malformations, its use is subject to stringent regulatory oversight in the EU, which mandates the implementation of a comprehensive PPP [35]. This program, established to mitigate the teratogenic risks, necessitates that women of childbearing potential engage in a series of precautionary measures before and during the course of treatment. Specifically, individuals are required to sign a formal risk acknowledgment form, thereby confirming their understanding of the potential risks posed by the medication. Women must undergo a thorough pregnancy screening, including a reliable pregnancy test, before the initiation of isotretinoin therapy. Furthermore, as a safeguard against unintended pregnancy, the program stipulates the use of two concurrent methods of contraception throughout the duration of treatment. These regulatory requirements are designed to minimize the risk of fetal exposure to isotretinoin, ensuring that the benefits of the medication outweigh its potential hazards when prescribed to women of reproductive age [36].

Thalidomide

This drug is a catastrophic teratogenic effects, has undergone a remarkable transformation in its clinical application. Initially prescribed as a sedative in the late 1950s and early 1960s, its use was tragically linked to severe birth defects, resulting in a public health crisis that irrevocably altered the landscape of pharmacovigilance and drug regulation [37]. However, subsequent research and clinical trials have revealed that thalidomide possesses therapeutic efficacy in treating certain malignancies and chronic conditions, most notably multiple myeloma, as well as complications associated with leprosy. Despite its renewed therapeutic potential, thalidomide remains subject to stringent regulatory controls, particularly within the EU. In the EU, thalidomide is distributed under a highly regulated and restricted program, designed to prevent the re-emergence of the severe teratogenic consequences witnessed in its initial use. To ensure patient safety, the drug is made available only through a comprehensive risk management framework [38]. This program mandates that patients seeking thalidomide treatment must be enrolled in a risk mitigation protocol, which includes strict eligibility criteria. Both patients and healthcare providers must satisfy a series of conditions before thalidomide can be prescribed. These safeguards are integral to the controlled administration of the drug, with continuous monitoring and compliance with regulatory standards being essential to minimize the potential risks of its use. This precautionary approach underscores the balance between the therapeutic benefits of thalidomide and the need to mitigate its inherent risks, reflecting the evolving paradigm of pharmacological safety in modern medicine.

Clopidogrel

An antiplatelet agent commonly employed in the management of cardiovascular conditions, serves as a potent blood-thinning medication that inhibits platelet aggregation [39]. While it is highly effective in preventing thrombotic events, its use is not without inherent risks, particularly the potential for bleeding complications. The risk of bleeding is a well-documented adverse effect, which can manifest in various forms, ranging from minor hematomas to life-threatening

hemorrhages. In certain clinical scenarios, particularly in patients undergoing procedures such as percutaneous coronary interventions (e.g., stent placement), the necessity for additional safety measures becomes paramount. These measures may include rigorous monitoring for signs of bleeding, adjustment of dosage, or in some cases, the restriction of clopidogrel use to specialists with expertise in managing its risks [40]. Furthermore, patients in high-risk categories – such as those with coexisting conditions like renal insufficiency or a history of gastrointestinal bleeding – may require increased vigilance and tailored therapeutic strategies to mitigate the potential for adverse outcomes. In these contexts, a multidisciplinary approach to patient management, encompassing both pharmacological and procedural considerations, is essential to optimize therapeutic efficacy while minimizing harm.

NP1: EU RMP

The complete understanding of the benefit-risk profile of a medicinal product remains limited at the time of its initial licensing and may evolve following approval. Consequently, this balance requires ongoing reassessment during the post-marketing phase when the product is used in clinical practice across a broader, more diverse patient population than in pre-marketing clinical trials. The dynamic nature of the benefit-risk balance necessitates a lifecycle approach, involving continuous evaluation and monitoring throughout the entire product lifecycle. In accordance with current EU legislation, which has been in effect since November 2005, Marketing Authorization Applicants are required to provide a comprehensive description of the risk management system as part of their drug licensing application for innovative products. For new chemical entities, biosimilars, and generics derived from reference products with identified risks, submission of an EU-RMP is mandatory [41]. The EU-RMP consists of a structured set of pharmacovigilance activities and interventions aimed at identifying, characterizing, preventing, or minimizing risks throughout the lifecycle of the drug. The primary goal of the EU-RMP is to ensure that the benefits of a medicinal product outweigh its risks to the greatest extent possible, both at the individual and population levels. For all medicinal products, the EU-RMP includes routine risk minimization activities (RMAs) designed to reduce the likelihood or severity of adverse drug reactions. A key distinction between the EU and the US regulatory frameworks is that EU-RMPs must be submitted as part of the marketing authorization application for all new active substances and in other specified scenarios [42]. This legislative requirement ensures that safety measures are considered early in the approval process. The objective of this study is to examine additional RMAs for medicinal products licensed through the EU's central authorization procedure. To the best of our knowledge, this is the first descriptive study to explore additional RMAs among centrally authorized products in the EU. Although not a primary focus of our analysis, it is conceivable that the safety profiles of newer products may differ from older ones, making additional RMAs more pertinent for newer drugs. However, our findings suggest no significant changes over time in the product classes most commonly associated with additional RMAs. Furthermore, the proposed additional RMAs for these products did not differ substantially, although the number of products with additional RMAs authorized before the new legislation was relatively limited. An additional concern pertains to the potential misuse of educational materials intended for risk minimization, where such materials might be co-opted for commercial purposes rather than fulfilling their intended safety objectives. Stringent monitoring of these additional RMAs is essential to mitigate this risk. New provisions within the pharmacovigilance legislation, to be implemented in July 2012, mandate the monitoring of the outcomes of additional RMAs, which is expected to further curtail this concern in the near future.

REGULATORY OVERSIGHT OF ARMMS IN EUROPE

The EMA and NCAs are responsible for overseeing the implementation and effectiveness of aRMMs, which are specific actions required when routine RMMs (such as labeling) are insufficient to mitigate identified risks. These measures may include restricted distribution, patient and HCP education, PPPs, and mandatory patient monitoring [43]. The MAH must submit a RMP to the EMA, detailing the proposed aRMMs, which are then reviewed and approved. The EMA ensures that the measures are appropriate and effectively implemented across EU member states. Ongoing surveillance, post-marketing studies, and data collection are used to assess the effectiveness of aRMMs, and adjustments can be made if necessary. The regulatory bodies also monitor compliance with these measures, ensuring that safety standards are maintained and that any new risks are quickly addressed to protect public health.

Control strategy

The first step involves identifying the specific risks associated with a drug, such as severe adverse reactions, misuse, or teratogenicity, based on clinical trial data, post-marketing surveillance, and other evidence. Once these risks are defined, appropriate aRMMs are implemented, such as restricted access programs, mandatory monitoring, patient registries, or healthcare provider training, designed to minimize harm. Following implementation, continuous monitoring through post-authorization studies, real-world surveillance, and feedback from healthcare providers and patients is crucial to assess the effectiveness of these measures in reducing adverse events. Ongoing evaluation is necessary to determine whether the aRMMs are achieving their goals, ensuring that the balance between risk and benefit remains favorable. This evaluation process includes reviewing safety data, considering stakeholder feedback, and performing cost-effectiveness analyses. If the RMMs are found to be insufficient or overly burdensome, adjustments can be made, including revising the RMP or modifying the monitoring requirements. A robust feedback loop is vital to adapt to emerging data and evolving patient needs, with regulatory bodies like the EMA overseeing compliance with safety regulations [44]. Ultimately, a control strategy for aRMMs aims to safeguard patient safety, maintain drug efficacy, and ensure that any risk-reducing interventions are aligned with regulatory standards and practical realities in healthcare settings.

Risk evaluation

The evaluation of aRMMs in Europe involves assessing both the effectiveness of these measures in reducing specific risks and the broader impact on healthcare systems, patients, and public health [45]. Initially, the key risks associated with a medicinal product must be identified, such as severe side effects, misuse potential, or teratogenicity. Effectiveness is then evaluated through post-authorization studies, real-world data, and surveillance systems to track whether the aRMMs successfully reduce adverse events and enhance patient safety. However, aRMMs can also have unintended consequences, such as increasing healthcare costs, creating access barriers, or adding administrative burdens on healthcare providers, which may impact overall patient care. Continuous monitoring, including feedback from HCPs and patients, is essential to ensure these measures remain relevant and effective. RMPs and pharmacovigilance systems, such as EudraVigilance, play a key role in the ongoing evaluation and adjustment of these risk mitigation strategies [46]. The ultimate goal is to balance the benefits of a pharmaceutical product with its risks, ensuring that safety measures do not unduly limit access to treatment or burden healthcare systems.

PROCESS INDICATORS

More than a quarter of newly approved medicinal products by the EMA are subject to aRMMs. These aRMMs are crucial in managing safety concerns associated with drugs that could have severe, adverse effects on patients, especially when the risks cannot be sufficiently controlled by conventional risk minimization strategies, such as the Summary of Product Characteristics and PILs [47]. The primary aim of these measures is to provide an additional layer of protection for patients, ensuring that the therapeutic benefits of a drug continue to outweigh the associated risks. As such, the evaluation of the effectiveness of aRMMs is essential for determining whether these interventions are achieving their intended objectives [48]. If the measures are not successful, further investigation is required to identify the root causes and determine which corrective

actions must be implemented [49]. Research conducted in this area has demonstrated that, up until 2015, only 31% of medicines with aRMMs had undergone a formal evaluation of the effectiveness of these risk mitigation strategies [50]. However, a trend of accelerated evaluation has been observed in more recent years, reflecting an increased emphasis on assessing the impact of these interventions. Risk minimization evaluations (RMEv) can adopt a range of methodologies, including studies that separately evaluate process indicators (e.g., adherence to protocols, completion of safety monitoring) or health outcomes (e.g., incidence of adverse drug reactions, hospitalizations). In some cases, hybrid approaches are employed, combining both process and outcome measures to offer a more comprehensive view of the effectiveness of the RMMs. Moreover, data collection for RMEv can occur through various means. Health and safety outcomes can be reported directly by participants, gathered prospectively, or retrieved from secondary data sources, such as electronic health records and national health databases. In some cases, medical chart abstraction or patient registries may also provide valuable insights into the real-world impact of the aRMMs [51]. While these approaches provide valuable data, the growing complexity of pharmaceutical safety necessitates the adoption of more robust, patient-level analyses. Correlating process indicators with health outcomes at the patient level enables a more holistic and accurate evaluation of how effectively the aRMMs are being implemented in clinical practice. Furthermore, effective evaluation of aRMMs can inform regulatory decision-making, allowing the EMA and other regulatory bodies to make timely adjustments to the measures as necessary. If certain aRMMs are found to be ineffective or burdensome, modifications may be made to streamline the measures or enhance their efficacy, ultimately improving patient safety [52]. Continuous monitoring and post-marketing surveillance also play a critical role in this process, as emerging safety concerns or new data may necessitate the adaptation of risk minimization strategies. While the evaluation of aRMMs has historically been limited, ongoing efforts are increasing their integration into post-marketing surveillance and safety monitoring. A more comprehensive and integrated approach to risk minimization evaluation, incorporating both process indicators and patient-level outcomes, is essential for ensuring the continued safety and efficacy of medicinal products. As the regulatory landscape evolves, the emphasis on evidence-based, real-time evaluations of risk minimization strategies will become an integral part of ensuring patient safety and optimizing therapeutic outcomes (Fig. 1).

TOOLS AND FRAMEWORKS FOR RISK EVALUATION OF ARMMS

The EMA offers a robust and methodical framework for the evaluation and implementation of risk minimization strategies, ensuring that pharmaceutical products marketed within the EU adhere to rigorous safety standards throughout their lifecycle. This framework incorporates several key components, each designed to facilitate the identification, management, and mitigation of risks associated with medicinal products:

RMPs

A cornerstone of the EMA's regulatory approach, every pharmaceutical product authorized in the EU is required to have a comprehensive RMP [53]. This plan outlines the specific measures that will be taken to identify potential risks associated with the product, assess their severity and likelihood, and implement appropriate strategies to minimize or eliminate those risks. The RMP also defines the methods for ongoing monitoring and evaluation of risks throughout the product's lifecycle. This dynamic document evolves based on emerging safety data and the outcomes of post-marketing surveillance.

Pharmacovigilance guidelines

The EMA's pharmacovigilance guidelines, which are codified under Directive 2010/84/EU and Regulation (EC) No 1235/2010, mandate that pharmaceutical companies continually monitor and report safety data to the EMA [54]. These guidelines establish clear legal requirements for the systematic collection, analysis, and submission of data regarding ADRs and other safety concerns. Furthermore, companies must assess whether aRMMs are necessary in response to emerging safety signals or changes in the risk profile of a product.

Post-marketing surveillance

An integral component of the risk management process, post-marketing surveillance involves the ongoing monitoring of a drug's safety profile once it is in widespread clinical use. This phase is critical for identifying rare or long-term adverse effects that may not have been detected during clinical trials. The EudraVigilance database plays a pivotal role in the EU's pharmacovigilance efforts by serving as a centralized repository for adverse drug reaction reports [55]. The database allows for the real-time tracking and evaluation of safety concerns, facilitating timely regulatory action to protect public health.

Periodic safety update reports (PSURS)

Pharmaceutical companies are required to submit PSURs at regular intervals to the EMA [56]. These reports provide a comprehensive summary of the safety data accumulated over a specified period and analyze the ongoing risk-benefit profile of the medicinal product. PSURs are essential for detecting potential safety issues that may not have been evident during earlier stages of the product's lifecycle and for ensuring that any necessary adjustments to risk minimization strategies are made in a timely manner.



Fig. 1: Process indicators

RCPs

In addition to the technical and regulatory aspects of risk management, the EMA emphasizes the importance of clear and effective risk communication. Pharmaceutical companies are required to develop and implement RCPs that inform HCPs, patients, and the public about the safety profile of a drug [57]. These plans ensure that stakeholders are aware of potential risks and the steps they can take to minimize those risks. Through targeted communication strategies, the EMA ensures that safety information is disseminated in a transparent, timely, and accessible manner.

Risk minimization evaluation

The effectiveness of risk minimization strategies is routinely evaluated by the EMA through a combination of data analysis and regulatory review processes. The EMA continuously assesses whether the implemented risk mitigation measures are achieving their intended outcomes and whether any adjustments are necessary. This evaluation process is essential for maintaining the safety of the public and ensuring that the benefits of a medicinal product continue to outweigh its risks [58]. The EMA also works in conjunction with national regulatory authorities to monitor the effectiveness of risk minimization programs across different EU member states.

Through this structured and comprehensive approach, the EMA ensures that the safety of pharmaceutical products is consistently prioritized, providing a framework that both protects public health and facilitates the safe use of medicines across Europe (Fig. 2).

CHALLENGES IN IMPLEMENTATION OF EU RISK MINIMIZATION MEASURES

In the EU, regulatory authorities may require MAHs to develop and implement RMMs to ensure the safe and effective use of medicines by patients [59]. These measures may include PPPs or protocols for monitoring patients for specific risk factors. The operationalization of RMM requirements is carried out by NCAs, who work in collaboration with HCPs to integrate these measures into clinical practice, ultimately reaching patients. Given the variability in the implementation pathways of specific RMMs, the process is inherently complex, as the goal is to alter the knowledge and behaviors of a broad spectrum of individuals, including patients, caregivers, consumers, and HCPs. This often necessitates coordination across various institutional structures and organizations, such as health authorities, academic and research institutions, HCP associations, and patient advocacy groups [60]. In addition, these stakeholders participate in healthcare at different levels – international, European, national, and subnational – which further complicates the implementation process. The Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA has acknowledged the challenges posed by this multifaceted stakeholder landscape in the implementation of risk minimization strategies [61]. In its revised impact strategy, the PRAC emphasized a shift in focus from conceptual development and guidance on measuring the impact of regulatory actions to prioritizing activities and regulatory tools that directly influence daily healthcare practices and are therefore relevant to patients, consumers, and HCPs. To enhance the effectiveness of RMM implementation and strengthen the engagement of the EU regulatory network with relevant stakeholders, it is crucial to understand how Clinical Practice Guidelines (CPGs) intersect with the RMM implementation pathway [62]. Accordingly, the aim of this study is to assess the extent to which RMMs are incorporated into the pertinent CPGs and to identify the factors that influence their inclusion.

COMPARISON WITH US RISK MANAGEMENT REGULATIONS

Risk management encompasses several key components: Risk identification and assessment, risk communication, risk monitoring, and risk treatment. Over recent decades, it has expanded across various industrial sectors, likely in response to increasing objective risks or as a form of "risk colonization." The concept of "risk colonization" refers to governance systems framing societal threats as risks in response to growing pressures to address governance failures [63]. In the realm of healthcare, analyses of pharmaceutical risk management remain notably scarce within the social science literature. This gap is addressed in this study by examining the emergence and implementation of risk management in pharmaceutical regulation within the EU and the US. The primary objective is to evaluate the extent to which this emergence reflects the phenomenon of "risk colonization" and to assess whether the implementation of risk management policies in these regions advances precautionary or permissive regulatory approaches, both absolutely and comparatively. Pharmaceutical product risk management represents a distinct aspect of the established "risk regulation regime" within drug regulation, which has been operational at both national and supranational levels, particularly within the EU [64]. However, existing literature on pharmaceutical risk regulation is either outdated, preceding the rise of risk management in the sector, or focused on other dimensions of regulation. It is critical to examine how social contexts – such as the interests, expertise, and markets – shape the regulatory frameworks. Despite the evolving context of pharmaceutical risk management and the growing role of the EU's supranational drug regulatory system, international comparisons of drug regulation often focus on the US and individual nations, neglecting the role of the EU's centralized regulatory framework [65]. Shifting focus from nation-states to the EU is essential, as the EU is increasingly responsible for regulating the risks and benefits of newly developed pharmaceutical products within Europe. The notion that risk regulation is best understood within its specific context suggests that international variations in prescription pharmaceutical risk management cannot be easily extrapolated from broader national regulatory styles in other sectors. Rather, these variations should be studied directly to uncover the precautionary or permissive characteristics of regulatory



Fig. 2: European Medicines Agency framework for risk minimization: A structured approach to drug safety

frameworks in different regions. Both in the EU and the US, the product label serves as a vital tool not only for risk communication to HCPs and patients but also as a mechanism that legitimizes permissive regulatory decisions, especially for products that offer minimal or no therapeutic advances over existing drugs [66]. Risk communication through labeling has been a cornerstone of pharmaceutical risk management used by all regulatory agencies, both before and after the formal introduction of "risk management" concepts into drug regulation. As exemplified by the Trovan case study; however, changes in labeling are often subject to negotiation between regulatory authorities and the drug's manufacturer [67,68].

RMP FOR MEDICINAL PRODUCTS

In the EU, the authorization of medicinal products is a prerequisite before they can be marketed for patient use. Authorization may be granted through several pathways, including national procedures, mutually recognized procedures, and the centralized procedure. A medicinal product is deemed authorized in the EU when, at the time of its approval, the benefits outweigh the risks for the target population, under the conditions specified in the product's labeling [69]. The overarching goal of the risk management system for medicinal products is to ensure that the benefit-risk balance is maximized to the greatest extent possible for both individual patients and the broader target population. A RMP serves as a comprehensive, multi-part document that is continuously updated by the MAH throughout the product's lifecycle. The RMP outlines the necessary actions to enhance the understanding of the medicinal product's safety profile and specifies the associated RMMs. The focus of this study is to explore how these RMPs contribute to safeguarding public health from the perspective of EU member states. Specifically, this research provides valuable data on RMPs assessed at the EU level, alongside quantitative data on safety communications, such as aRMMs and Direct HCP Communications, which are assessed and approved at the national level [70]. By utilizing a smaller EU member state as a case study – where resource constraints are often magnified by the country's size – this study offers insights into the practical challenges encountered by national regulators during the RMP assessment process and the management of safety information. The experiences and lessons derived from these regulatory activities are of significant relevance not only to the pharmaceutical industry but also to other regulatory bodies, including the EMA [71]. Furthermore, this study identifies the varying RMP requirements across different global regions and countries, shedding light on the challenges these disparities present to the harmonization of risk management practices in the pharmaceutical industry.

CONCLUSION

The evaluation of aRMMs in Europe is a complex but essential process to ensure that the benefits of a medicine outweigh its risks. It involves a combination of pre-market assessments, real-world surveillance, and ongoing monitoring of patient outcomes. Effective risk evaluation requires assessing the direct impact of the measures on patient safety, as well as evaluating any unintended consequences such as burden on healthcare systems or reduced access to essential treatments. By carefully weighing these factors, regulators can ensure that the benefits of a drug are maximized, and its risks are minimized to the greatest extent possible.

ETHICAL APPROVAL

Not applicable.

CONFLICTS OF INTEREST

Nil.

REFERENCES

1. Hines PA, Gonzalez-Quevedo R, Lambert AI, Janssens R, Freischem B, Torren Edo J, *et al*. Regulatory science to 2025: An analysis of stakeholder responses to the European medicines agency's strategy. Front Med (Lausanne). 2020 Sep 23;7:508. doi: 10.3389/fmed.2020.00508, PMID: 33072771
2. Bolcato M, Russo M, Trentino K, Isbister J, Rodriguez D, Aprile A. Patient blood management: The best approach to transfusion medicine risk management. Transfus Apher Sci. 2020 Aug 1;59(4):102779. doi: 10.1016/j.transci.2020.102779, PMID: 32359972
3. Kulkarni GP, Patil LV. Analysis of adverse drug reactions spontaneously reported to adverse drug monitoring centre of a tertiary care Hospital prospective study. Int J Curr Pharm Res. 2018;10(1):23-5. doi: 10.22159/ijcpr.2018v10i1.24403
4. Goedecke T, Martirosyan L, Gault N, Seifert K, Morales DR, Bahri P, *et al*. Studying the impact of European union regulatory interventions for minimising risks from medicines: Lessons learnt and recommendations. Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5874. doi: 10.1002/pds.5874, PMID: 39092454
5. Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, *et al*. The path to a better biomarker: Application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 Apr;250(5):667-84. doi: 10.1002/path.5406, PMID: 32129476
6. Sankeshwari S, Gangadharappa HV, Asha Spandana KM, Eliyas A, Thirumaleshwar S, Harsha Vardhan PV. A review on the solid oral dosage form for pediatrics, regulatory aspects, challenges involved during the formulation, and toxicity of the excipients used in pediatric formulation. Int J Appl Pharm. 2023;15(3):12-27. doi: 10.22159/ijap.2023v15i3.47313
7. Kataria BC, Mehta D, Chhaiya SB. Approval of new nervous system drugs in India compared with the us and eu. Int J Pharm Pharm Sci. 2012;4(4):706-9.
8. Zhang M, Marklund H, Dhawan N, Gupta A, Levine S, Finn C. Adaptive risk minimization: Learning to adapt to domain shift. Adv Neural Inf Process Syst. 2021 Dec 6;34:23664-78.
9. Hugman B, Skalli S. Pharmacovigilance and risk communication for the safe use of herbal and traditional medicines: How to promote evidence and keep people safe. In: Barnes J, editor. Pharmacovigilance for Herbal and Traditional Medicines: Advances, Challenges and International Perspectives. Cham: Springer International Publishing; 2022 Aug 12. p. 261-76. doi: 10.1007/978-3-031-07275-8-15
10. Benami E, Jin Z, Carter MR, Ghosh A, Hijmans RJ, Hobbs A, *et al*. Uniting remote sensing, crop modelling and economics for agricultural risk management. Nat Rev Earth Environ. 2021 Feb;2(2):140-59. doi: 10.1038/s43017-020-00122-y
11. Kumar RD. The phases of clinical trials: From preclinical studies to post-market surveillance. Glob J Med Clin Case Rep. 2024 Dec 26;11:55-65. doi: 10.17352/2455-5282.000189
12. Altıntaş Aykan D, Ergün Y. Isotretinoin: Still the cause of anxiety for teratogenicity. Dermatol Ther. 2020 Jan;33(1):e13192. doi: 10.1111/dth.13192, PMID: 31837244
13. Zhang H, Hua D, Huang C, Samal SK, Xiong R, Sauvage F, *et al*. Materials and technologies to combat counterfeiting of pharmaceuticals: Current and future problem tackling. Adv Mater. 2020 Mar;32(11):e1905486. doi: 10.1002/adma.201905486, PMID: 32009266
14. Tomasone JR, Kauffeldt KD, Chaudhary R, Brouwers MC. Effectiveness of guideline dissemination and implementation strategies on health care professionals' behaviour and patient outcomes in the cancer care context: A systematic review. Implement Sci. 2020 Dec;15(1):41. doi: 10.1186/s13012-020-0971-6, PMID: 32493348
15. Dernoncourt A, Liabeuf S, Bennis Y, Masmoudi K, Bodeau S, Laville S, *et al*. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the world health organization pharmacovigilance database (VigiBase®). BioDrugs. 2023 Jan;37(1):73-87. doi: 10.1007/s40259-022-00564-4, PMID: 36401769
16. Rašković A, Steinbach M, Mugoša S, Baljak J, Prodanović D, Sabo S, *et al*. Patient information leaflets: How do patients comprehend and understand drug information? Arch Pharm Pract. 2024;15(1)(1-2024):7-11. doi: 10.51847/n2jlaSAlbK
17. Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022 Sep 1;237:108172. doi: 10.1016/j.pharmthera.2022.108172, PMID: 35304222
18. Renn O. Risk communication: Insights and requirements for designing successful communication programs on health and environmental hazards. In: Heath RL, O'Hair HD, editors. Handbook of Risk and

Crisis Communication. United Kingdom: Routledge; 2020 Oct 28. p. 80-98. doi: 10.4324/9781003070726-5
19. Pore AV, Bais SK, Kamble MM. Pharmacovigilance in clinical research. Int J Pharm Herb Technol. 2024;2(1):759-75.
20. Butler D, Vucic K, Straus S, Cupelli A, Micallef B, Serracino-Inglott A, *et al*. Regulatory experience of handling risk management plans (RMPs) for medicinal products in the EU. Expert Opin Drug Saf. 2021 Jul 3;20(7):815-26. doi: 10.1080/14740338.2021.1909569, PMID: 33843379
21. Chatzopoulou S, Eriksson NL, Eriksson D. Improving risk assessment in the European food safety authority: Lessons from the European medicines agency. Front Plant Sci. 2020 Apr 6;11:349. doi: 10.3389/fpls.2020.00349, PMID: 32318080
22. Heng H, Jazayeri D, Shaw L, Kiegaldie D, Hill AM, Morris ME. Hospital falls prevention with patient education: A scoping review. BMC Geriatr. 2020 Dec;20(1):140. doi: 10.1186/s12877-020-01515-w, PMID: 32293298
23. Staub C, Fuchs C, Siegrist M. Risk perception and acceptance of health warning labels on wine. Food Qual Prefer. 2022 Mar 1;96:104435. doi: 10.1016/j.foodqual.2021.104435
24. Bruinen De Bruin Y, Lequarre AS, McCourt J, Clevestig P, Pigazzani F, Zare Jeddi M, *et al*. Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic. Saf Sci. 2020 Aug 1;128:104773. doi: 10.1016/j.ssci.2020.104773, PMID: 32296266
25. Goswami S, Eckert L, Sturgill M, Ramos R, Bridgeman MB. Patient education on self-administration of insulin via pen: An interprofessional team-based educational initiative. J Interprof Educ Pract. 2023 Sep 1;32:100663. doi: 10.1016/j.xjep.2023.100663
26. Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: Strategies to address key barriers within the treatment system. NAM Perspect. 2020 Apr 27;2020:10-31478. doi: 10.31478/202004b, PMID: 35291732
27. Paczkowska A, Hoffmann K, Kus K, Kopciuch D, Zaprutko T, Ratajczak P, *et al.* Impact of patient knowledge on hypertension treatment adherence and efficacy: A single-centre study in Poland. Int J Med Sci. 2021 Jan 1;18(3):852-60. doi: 10.7150/ijms.48139, PMID: 33437222
28. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, *et al.* Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: Challenges and opportunities. Nat Rev Neurol. 2020 Jul 15;16(7):381-400. doi: 10.1038/s41582-020-0362-2, PMID: 32541893
29. Battino D, Tomson T, Bonizzoni E, Craig J, Perucca E, Sabers A, *et al*. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024 May 1;81(5):481-9. doi: 10.1001/jamaneurol.2024.0258, PMID: 38497990
30. McGrath SP, McGovern KM, Perreard IM, Huang V, Moss LB, Blike GT. Inpatient respiratory arrest associated with sedative and analgesic medications: Impact of continuous monitoring on patient mortality and severe morbidity. J Patient Saf. 2021 Dec 1;17(8):557-61. doi: 10.1097/PTS.0000000000000696, PMID: 32175965
31. Gaudio M, Konstantara E, Joy M, Van Vlymen J, De Lusignan S. Valproate prescription to women of childbearing age in English primary care: Repeated cross-sectional analyses and retrospective cohort study. BMC Pregnancy Childbirth. 2022 Jan 27;22(1):73. doi: 10.1186/s12884-021-04351-x, PMID: 35086478
32. National Research Council, Division on Earth, Life Studies, Board on Environmental Studies. Committee to Review the IRIS Process. Review of EPA's Integrated Risk Information System (IRIS) Process. United States: National Academies Press; 2014.
33. Fraser AG, Byrne RA, Kautzner J, Butchart EG, Szymański P, Leggeri I, *et al.* Implementing the new European regulations on medical devices-clinical responsibilities for evidence-based practice: A report from the regulatory affairs committee of the European society of cardiology. Eur Heart J. 2020 Jul 14;41(27):2589-96. doi: 10.1093/eurheartj/ehaa382, PMID: 32484542
34. De Caux D, Mariappa G, Perera G, Girling J. Prescribing for pregnancy: Chronic skin diseases. Drug Ther Bull. 2023 Apr 1;61(4):55-60. doi: 10.1136/dtb.2022.000036, PMID: 36990470
35. Heyward J, Olson L, Sharfstein JM, Stuart EA, Lurie P, Alexander GC. Evaluation of the extended-release/long-acting opioid prescribing risk evaluation and mitigation strategy program by the US food and drug administration: A review. JAMA Intern Med. 2020 Feb 1;180(2):301-9. doi: 10.1001/jamainternmed.2019.5459, PMID: 31886822
36. Reinold J, Kollhorst B, Wentzell N, Platzbecker K, Haug U. Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: A population-based study. PLoS Med. 2024 Jan 25;21(1):e1004339. doi: 10.1371/journal.pmed.1004339, PMID: 38271295
37. Shenfadu DR. Synthesis and biological study of pyrazoles, amino-pyrimidines and malononitriles derived from cyclic imides. Int J Chem Res. 2012;2016;March:3-312.
38. Klatte K, Pauli-Magnus C, Love SB, Sydes MR, Benkert P, Bruni N, *et al*. Monitoring strategies for clinical intervention studies. Cochrane Database Syst Rev. 2021;12(12):MR000051. doi: 10.1002/14651858.MR000051.pub2, PMID: 34878168
39. Ivask M, Kurvits K, Uusküla M, Juppo A, Laius O, Siven M. Compliance with pregnancy prevention recommendations for isotretinoin following the amendment of the European union pregnancy prevention program: A repeat study in Estonia. Drugs Real World Outcomes. 2024 Mar;11(1):91-8. doi: 10.1007/s40801-023-00381-3, PMID: 37462893
40. Shroukh WA. Risk Management of Thalidomide in Jordan: An Application of the World Health Organization's Health Systems Framework. UK: University Manchester; 2020.
41. Dhara S, Moore EE, Yaffe MB, Moore HB, Barrett CD. Modern management of bleeding, clotting, and coagulopathy in trauma patients: What is the role of viscoelastic assays? Curr Trauma Rep. 2020 Mar;6(1):69-81. doi: 10.1007/s40719-020-00183-w, PMID: 32864298
42. Marcucci R, Berteotti M, Gragnano F, Galli M, Cavallari I, Renda G, *et al*. Monitoring antiplatelet therapy: Where are we now? J Cardiovasc Med (Hagerstown). 2023 Apr 1;24(Suppl 1):e24-35. doi: 10.2459/JCM.0000000000001406, PMID: 36729588
43. Allocati E, Bertele' V, Gerardi C, Garattini S, Banzi R. Clinical evidence supporting the marketing authorization of biosimilars in Europe. Eur J Clin Pharmacol. 2020 Apr;76(4):557-66. doi: 10.1007/s00228-019-02805-y, PMID: 31897530
44. Oberweis CV, Marchal JA, López-Ruiz E, Gálvez-Martín P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Eng Part B Rev. 2020 Apr 1;26(2):181-96. doi: 10.1089/ten.TEB.2019.0315, PMID: 31910099
45. Treacy J, Morrato EH, Horne R, Wolf MS, Bakhai A, Wilson MC, *et al*. Behavioral science: Enhancing our approach to the development of effective additional risk minimization strategies. Drug Saf. 2024 Aug;47(8):733-43. doi: 10.1007/s40264-024-01420-w, PMID: 38594553
46. Lewis DJ, McCallum JF. Utilizing advanced technologies to augment pharmacovigilance systems: Challenges and opportunities. Ther Innov Regul Sci. 2020 Jul;54(4):888-99. doi: 10.1007/s43441-019-00023-3, PMID: 32557311
47. Hughes JE, Buckley N, Looney Y, Kirwan G, Mullooly M, Bennett KE. Evaluating awareness, knowledge and practice of healthcare professionals following implementation of a revised pregnancy prevention programme for isotretinoin in Ireland: A multi-stakeholder cross-sectional study. Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):137-47. doi: 10.1002/pds.5538, PMID: 36073295
48. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. The Ethical Challenges of Emerging Medical Technologies. United Kingdom: Routledge; 2020 Sep 10. p. 41-8. doi: 10.4324/9781003074984-3
49. Albassam A, Hughes DA. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. Eur J Clin Pharmacol. 2021 Feb;77(2):251-60. doi: 10.1007/s00228-020-03003-x, PMID: 32989529
50. Essink SC, Zomerdijk IM, Straus SM, Gardarsdottir H, De Bruin ML. Duration of effectiveness evaluation of additional risk minimisation measures for centrally authorised medicinal products in the EU between 2012 and 2021. Drug Saf. 2023 Oct;46(10):1007-20. doi: 10.1007/s40264-023-01341-0, PMID: 37658281
51. Sedrakyan A, Marinac-Dabic D, Campbell B, Aryal S, Baird CE, Goodney P, *et al*. Advancing the real-world evidence for medical devices through coordinated registry networks. BMJ Surg Interv Health Technol. 2022 Nov 11;4(Suppl 1):e000123. doi: 10.1136/bmjsit-2021-000123, PMID: 36393894
52. Xie X, Song Q, Dai C, Cui S, Tang R, Li S, *et al.* Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: A phase I/II clinical trial. Gen Psychiatr. 2023 Oct 11;36(5):e101143. doi: 10.1136/gpsych-2023-101143, PMID: 37859748
53. Holm JE, Ruppert JG, Ramsden SD. Impact of changing regulations and the dynamic nature of European risk management plans for human medicines on the lifecycle of safety concerns. Pharmaceut

Med. 2022 Feb;36(1):33-46. doi: 10.1007/s40290-021-00414-8, PMID: 35099785

54. Trifirò G, Crisafulli S. A new era of pharmacovigilance: Future challenges and opportunities. Front Drug Saf Regul. 2022 Feb 25;2:866898. doi: 10.3389/fdsfr.2022.866898
55. Peters T, Soanes N, Abbas M, Ahmad J, Delumeau JC, Herrero-Martinez E, *et al*. Effective pharmacovigilance system development: EFPIA-IPVG consensus recommendations. Drug Saf. 2021 Jan;44(1):17-28. doi: 10.1007/s40264-020-01008-0, PMID: 33289904
56. Sharma R, Kant K, Kumar A. Overview of periodic safety update reports: Where have we reached? Appl Clin Res Clin Trials Regul Aff. 2020 Apr 1;7(1):4-11. doi: 10.2174/2213476X06666190823151514
57. Alharbi AB, Berrou I, Umaru N, Al Hamid A, Shebl NA. Factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: A systematic review. Res Social Adm Pharm. 2023 Jan 1;19(1):28-56. doi: 10.1016/j.sapharm.2022.07.003, PMID: 35989221
58. Kürzinger ML, Douarin L, Uzun I, El-Haddad C, Hurst W, Juhaeri J, *et al*. Structured benefit-risk evaluation for medicinal products: Review of quantitative benefit-risk assessment findings in the literature. Ther Adv Drug Saf. 2020 Dec;11:1-12. doi: 10.1177/2042098620976951, PMID: 33343857
59. Hoeve CE, Francisca RD, Zomerdijk I, Sturkenboom MC, Straus SM. Description of the risk management of medication errors for centrally authorised products in the European Union. Drug Saf. 2020 Jan;43(1):45-55. doi: 10.1007/s40264-019-00874-7, PMID: 31617081
60. Fichtenberg C, Delva J, Minyard K, Gottlieb LM. Health and human services integration: Generating sustained health and equity improvements. Health Aff (Millwood). 2020 Apr 1;39(4):567-73. doi: 10.1377/hlthaff.2019.01594, PMID: 32250685
61. Flynn R, Hedenmalm K, Murray-Thomas T, Pacurariu A, Arlett P, Shepherd H, *et al*. Ability of primary care health databases to assess medicinal products discussed by the European Union pharmacovigilance risk assessment committee. Clin Pharmacol Ther. 2020 Apr;107(4):957-65. doi: 10.1002/cpt.1775, PMID: 31955404
62. Shi J, Chen X, Hu H, Ung CO. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557, PMID: 37213606
63. Janssen M, Brous P, Estevez E, Barbosa L, Janowski T. Data governance: Organizing data for trustworthy artificial intelligence. Gov Inf Q. 2020 Jul 1;37(3):101493. doi: 10.1016/j.giq.2020.101493
64. Wright JS, Doukas D. Challenges to sovereign ambitions: Forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union. Health Econ Policy Law. 2021 Jul;16(3):256-72. doi: 10.1017/S174413312000016X, PMID: 32583755
65. Rimkutė D, Mazepus H. A widening authority-legitimacy gap in EU regulatory governance? An experimental study of the European medicines agency's legitimacy in health security regulation. J Eur Public Policy. 2023 Jul 3;30(7):1406-30. doi: 10.1080/13501763.2023.2171091
66. Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, *et al*. Postmarket safety communication for protection of public health: A comparison of regulatory policy in Australia, Canada, the European Union, and the United States. Clin Pharmacol Ther. 2021 Jun;109(6):1424-42. doi: 10.1002/cpt.2010, PMID: 32767557
67. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): A comparative analysis. Lancet Digit Health. 2021 Mar 1;3(3):e195-203. doi: 10.1016/S2589-7500(20)30292-2, PMID: 33478929
68. Ponnapalli R, Divya MS, Raju KV, Nori LP. Regulatory framework: Vaccine development in us, India and eu. Int J Appl Pharm. 2023;15(2):63-71. doi: 10.22159/ijap.2023v15i2.46723
69. Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European medicines agency (2017-2021). Value Health. 2023 Jun 1;26(6):893-901. doi: 10.1016/j.jval.2023.01.017, PMID: 36746305
70. Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European medicines agency between 2016 and 2021. Clin Pharmacol Ther. 2023 Dec;114(6):1285-92. doi: 10.1002/cpt.3034, PMID: 37634124
71. Singh S, Sharma MP, Misra G. Regulatory bodies. In: Quality Control and Regulatory Aspects for Biologicals. United States: CRC Press; 2024 Apr 22. p. 137-59. doi: 10.1201/9781032697444-9